ID   CHLE_HUMAN              Reviewed;         602 AA.
AC   P06276; A8K7P8;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   07-APR-2021, entry version 220.
DE   RecName: Full=Cholinesterase;
DE            EC=3.1.1.8;
DE   AltName: Full=Acylcholine acylhydrolase;
DE   AltName: Full=Butyrylcholine esterase;
DE   AltName: Full=Choline esterase II;
DE   AltName: Full=Pseudocholinesterase;
DE   Flags: Precursor;
GN   Name=BCHE; Synonyms=CHE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetus;
RX   PubMed=3035536; DOI=10.1073/pnas.84.11.3555;
RA   Prody C.A., Zevin-Sonkin D., Gnatt A., Goldberg O., Soreq H.;
RT   "Isolation and characterization of full-length cDNA clones coding for
RT   cholinesterase from fetal human tissues.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:3555-3559(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=3477799; DOI=10.1073/pnas.84.19.6682;
RA   McTiernan C., Adkins S., Chatonnet A., Vaughan T.A., Bartels C.F., Kott M.,
RA   Rosenberry T.L., la Du B.N., Lockridge O.;
RT   "Brain cDNA clone for human cholinesterase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6682-6686(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2322535; DOI=10.1021/bi00453a015;
RA   Arpagaus M., Kott M., Vatsis K.P., Bartels C.F., la Du B.N., Lockridge O.;
RT   "Structure of the gene for human butyrylcholinesterase. Evidence for a
RT   single copy.";
RL   Biochemistry 29:124-131(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-567.
RC   TISSUE=Stomach;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 29-602, AND SIGNAL SEQUENCE CLEAVAGE SITE.
RC   TISSUE=Plasma;
RX   PubMed=3542989;
RA   Lockridge O., Bartels C.F., Vaughan T.A., Wong C.K., Norton S.E.,
RA   Johnson L.L.;
RT   "Complete amino acid sequence of human serum cholinesterase.";
RL   J. Biol. Chem. 262:549-557(1987).
RN   [7]
RP   PROTEIN SEQUENCE OF 29-37; 43-68; 71-163; 167-290; 294-522; 528-543 AND
RP   549-602, SIGNAL SEQUENCE CLEAVAGE SITE, GLYCOSYLATION, AND
RP   HOMOTETRAMERIZATION.
RC   TISSUE=Plasma;
RX   PubMed=20946535; DOI=10.1111/j.1423-0410.2010.01415.x;
RA   Weber A., Butterweck H., Mais-Paul U., Teschner W., Lei L., Muchitsch E.M.,
RA   Kolarich D., Altmann F., Ehrlich H.J., Schwarz H.P.;
RT   "Biochemical, molecular and preclinical characterization of a double-virus-
RT   reduced human butyrylcholinesterase preparation designed for clinical
RT   use.";
RL   Vox Sang. 100:285-297(2011).
RN   [8]
RP   PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BONDS.
RX   PubMed=3115973;
RA   Lockridge O., Adkins S., la Du B.N.;
RT   "Location of disulfide bonds within the sequence of human serum
RT   cholinesterase.";
RL   J. Biol. Chem. 262:12945-12952(1987).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-509 AND ASN-514.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-45; ASN-85; ASN-369; ASN-483;
RP   ASN-509 AND ASN-514.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [11]
RP   GLYCOSYLATION AT ASN-45; ASN-85; ASN-134; ASN-269; ASN-284; ASN-369 AND
RP   ASN-483, AND CHARACTERIZATION OF GLYCOSYLATION.
RX   PubMed=18203274; DOI=10.1002/pmic.200700720;
RA   Kolarich D., Weber A., Pabst M., Stadlmann J., Teschner W., Ehrlich H.,
RA   Schwarz H.P., Altmann F.;
RT   "Glycoproteomic characterization of butyrylcholinesterase from human
RT   plasma.";
RL   Proteomics 8:254-263(2008).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND SUBUNIT.
RX   PubMed=19542320; DOI=10.1124/mol.109.055665;
RA   Chilukuri N., Duysen E.G., Parikh K., diTargiani R., Doctor B.P.,
RA   Lockridge O., Saxena A.;
RT   "Adenovirus-transduced human butyrylcholinesterase in mouse blood functions
RT   as a bioscavenger of chemical warfare nerve agents.";
RL   Mol. Pharmacol. 76:612-617(2009).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-134 AND ASN-284.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [14]
RP   GLYCOSYLATION AT ASN-284.
RX   PubMed=19139490; DOI=10.1074/mcp.m800504-mcp200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F., Zheng Z.B.,
RA   Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y., Zhang Y.K., Deng Y.L.,
RA   Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core fucosylated
RT   glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [15]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=19452557; DOI=10.1002/prot.22442;
RA   Amitay M., Shurki A.;
RT   "The structure of G117H mutant of butyrylcholinesterase: nerve agents
RT   scavenger.";
RL   Proteins 77:370-377(2009).
RN   [16]
RP   PHOSPHORYLATION AT SER-226.
RX   PubMed=22444575; DOI=10.1016/j.aca.2012.02.023;
RA   Aryal U.K., Lin C.T., Kim J.S., Heibeck T.H., Wang J., Qian W.J., Lin Y.;
RT   "Identification of phosphorylated butyrylcholinesterase in human plasma
RT   using immunoaffinity purification and mass spectrometry.";
RL   Anal. Chim. Acta 723:68-75(2012).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND VARIANT BCHED ASP-232.
RX   PubMed=25054547; DOI=10.1371/journal.pone.0101552;
RA   Delacour H., Lushchekina S., Mabboux I., Bousquet A., Ceppa F.,
RA   Schopfer L.M., Lockridge O., Masson P.;
RT   "Characterization of a novel BCHE 'silent' allele: point mutation
RT   (p.Val204Asp) causes loss of activity and prolonged apnea with
RT   suxamethonium.";
RL   PLoS ONE 9:E101552-E101552(2014).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-557 IN COMPLEX WITH SUBSTRATE,
RP   SUBUNIT, GLYCOSYLATION AT ASN-85; ASN-134; ASN-269; ASN-369 AND ASN-513,
RP   DISULFIDE BONDS, AND ACTIVE SITE.
RX   PubMed=12869558; DOI=10.1074/jbc.m210241200;
RA   Nicolet Y., Lockridge O., Masson P., Fontecilla-Camps J.C., Nachon F.;
RT   "Crystal structure of human butyrylcholinesterase and of its complexes with
RT   substrate and products.";
RL   J. Biol. Chem. 278:41141-41147(2003).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 29-557 IN COMPLEX WITH
RP   ECHOTHIOPHATE, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-85; ASN-134;
RP   ASN-269; ASN-369 AND ASN-513.
RX   PubMed=15667209; DOI=10.1021/bi048238d;
RA   Nachon F., Asojo O.A., Borgstahl G.E.O., Masson P., Lockridge O.;
RT   "Role of water in aging of human butyrylcholinesterase inhibited by
RT   echothiophate: the crystal structure suggests two alternative mechanisms of
RT   aging.";
RL   Biochemistry 44:1154-1162(2005).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS), DISULFIDE BONDS, GLYCOSYLATION AT
RP   ASN-85; ASN-134; ASN-369 AND ASN-513, AND SUBUNIT.
RX   PubMed=17768338; DOI=10.1107/s1744309107037335;
RA   Ngamelue M.N., Homma K., Lockridge O., Asojo O.A.;
RT   "Crystallization and X-ray structure of full-length recombinant human
RT   butyrylcholinesterase.";
RL   Acta Crystallogr. F 63:723-727(2007).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 29-557 IN COMPLEX WITH MERCURY
RP   IONS AND BUTANOIC ACID, DISULFIDE BONDS, GLYCOSYLATION AT ASN-85; ASN-134;
RP   ASN-269; ASN-369 AND ASN-513, AND ACTIVITY REGULATION.
RX   PubMed=17355286; DOI=10.1111/j.1742-4658.2007.05732.x;
RA   Frasco M.F., Colletier J.-P., Weik M., Carvalho F., Guilhermino L.,
RA   Stojan J., Fournier D.;
RT   "Mechanisms of cholinesterase inhibition by inorganic mercury.";
RL   FEBS J. 274:1849-1861(2007).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 29-557 IN COMPLEX WITH TABUN,
RP   ACTIVITY REGULATION, IDENTIFICATION BY MASS SPECTROMETRY, AND GLYCOSYLATION
RP   AT ASN-85; ASN-134; ASN-284; ASN-369 AND ASN-513.
RX   PubMed=18975951; DOI=10.1021/ja804941z;
RA   Carletti E., Li H., Li B., Ekstroem F., Nicolet Y., Loiodice M., Gillon E.,
RA   Froment M.T., Lockridge O., Schopfer L.M., Masson P., Nachon F.;
RT   "Aging of cholinesterases phosphylated by tabun proceeds through O-
RT   dealkylation.";
RL   J. Am. Chem. Soc. 130:16011-16020(2008).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-557 IN COMPLEX WITH TABUN
RP   ANALOGS, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   GLYCOSYLATION AT ASN-85; ASN-134; ASN-269; ASN-284; ASN-369 AND ASN-513,
RP   AND ACTIVITY REGULATION.
RX   PubMed=19368529; DOI=10.1042/bj20090091;
RA   Carletti E., Aurbek N., Gillon E., Loiodice M., Nicolet Y.,
RA   Fontecilla-Camps J.C., Masson P., Thiermann H., Nachon F., Worek F.;
RT   "Structure-activity analysis of aging and reactivation of human
RT   butyrylcholinesterase inhibited by analogues of tabun.";
RL   Biochem. J. 421:97-106(2009).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 29-557 IN COMPLEX WITH TACRINE,
RP   DISULFIDE BOND, AND GLYCOSYLATION AT ASN-85; ASN-134; ASN-269; ASN-284;
RP   ASN-369 AND ASN-513.
RX   PubMed=23679855; DOI=10.1042/bj20130013;
RA   Nachon F., Carletti E., Ronco C., Trovaslet M., Nicolet Y., Jean L.,
RA   Renard P.Y.;
RT   "Crystal structures of human cholinesterases in complex with huprine W and
RT   tacrine: elements of specificity for anti-Alzheimer's drugs targeting
RT   acetyl- and butyryl-cholinesterase.";
RL   Biochem. J. 453:393-399(2013).
RN   [26]
RP   VARIANT BCHED GLY-98.
RX   PubMed=2915989; DOI=10.1073/pnas.86.3.953;
RA   McGuire M.C., Nogueira C.P., Bartels C.F., Lightstone H., Hajra A.,
RA   van der Spek A.F.L., Lockridge O., la Du B.N.;
RT   "Identification of the structural mutation responsible for the dibucaine-
RT   resistant (atypical) variant form of human serum cholinesterase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:953-957(1989).
RN   [27]
RP   VARIANT BCHED VAL-525.
RX   PubMed=1349196;
RA   Bartels C.F., James K., La Du B.N.;
RT   "DNA mutations associated with the human butyrylcholinesterase J-variant.";
RL   Am. J. Hum. Genet. 50:1104-1114(1992).
RN   [28]
RP   VARIANTS BCHED MET-271 AND VAL-418.
RX   PubMed=1415224;
RA   Nogueira C.P., Bartels C.F., McGuire M.C., Adkins S., Lubrano T.,
RA   Rubinstein H.M., Lightstone H., Van Der Spek A.F.L., Lockridge O.,
RA   La Du B.N.;
RT   "Identification of two different point mutations associated with the
RT   fluoride-resistant phenotype for human butyrylcholinesterase.";
RL   Am. J. Hum. Genet. 51:821-828(1992).
RN   [29]
RP   VARIANT BCHED ARG-393.
RX   PubMed=1611188; DOI=10.2169/internalmedicine.31.357;
RA   Hada T., Muratani K., Ohue T., Imanishi H., Moriwaki Y., Itoh M., Amuro Y.,
RA   Higashino K.;
RT   "A variant serum cholinesterase and a confirmed point mutation at Gly-365
RT   to Arg found in a patient with liver cirrhosis.";
RL   Intern. Med. 31:357-362(1992).
RN   [30]
RP   VARIANTS BCHED GLY-98 AND MET-170.
RX   PubMed=1306123; DOI=10.1097/00008571-199210000-00006;
RA   Jensen F.S., Bartels C.F., La Du B.N.;
RT   "Structural basis of the butyrylcholinesterase H-variant segregating in two
RT   Danish families.";
RL   Pharmacogenetics 2:234-240(1992).
RN   [31]
RP   VARIANTS BCHED PRO-278; ARG-393; SER-446; CYS-543 AND THR-567.
RX   PubMed=7634491; DOI=10.1016/0009-8981(95)06014-1;
RA   Maekawa M., Sudo K., Kanno T., Kotani K., Dey D.C., Ishikawa J., Izumi M.,
RA   Etoh K.;
RT   "Genetic basis of the silent phenotype of serum butyrylcholinesterase in
RT   three compound heterozygotes.";
RL   Clin. Chim. Acta 235:41-57(1995).
RN   [32]
RP   VARIANT BCHED ILE-358.
RX   PubMed=8680411; DOI=10.1002/humu.1380060411;
RA   Iida S., Kinoshita M., Fujii H., Moriyama Y., Nakamura Y., Yura N.,
RA   Moriwaki K.;
RT   "Mutations of human butyrylcholinesterase gene in a family with
RT   hypocholinesterasemia.";
RL   Hum. Mutat. 6:349-351(1995).
RN   [33]
RP   VARIANTS BCHED CYS-61; SER-65; PHE-153; GLU-198; GLY-226; THR-229; ARG-499
RP   AND LEU-546, AND CHARACTERIZATION OF VARIANTS BCHED SER-65; PHE-153;
RP   GLU-198; ARG-499 AND LEU-546.
RX   PubMed=8554068;
RA   Primo-Parmo S.L., Bartels C.F., Wiersema B., van der Spek A.F.L.,
RA   Innis J.W., La Du B.N.;
RT   "Characterization of 12 silent alleles of the human butyrylcholinesterase
RT   (BCHE) gene.";
RL   Am. J. Hum. Genet. 58:52-64(1996).
RN   [34]
RP   VARIANT BCHED CYS-156.
RX   PubMed=9543549; DOI=10.1046/j.1469-1809.1997.6160491.x;
RA   Hidaka K., Iuchi I., Tomita M., Watanabe Y., Minatogawa Y., Iwasaki K.,
RA   Gotoh K., Shimizu C.;
RT   "Genetic analysis of a Japanese patient with butyrylcholinesterase
RT   deficiency.";
RL   Ann. Hum. Genet. 61:491-496(1997).
RN   [35]
RP   VARIANT BUTYRYLCHOLINESTERASE DEFICIENCY ILE-358.
RX   PubMed=9388484; DOI=10.1006/bbrc.1997.7658;
RA   Sudo K., Maekawa M., Akizuki S., Magara T., Ogasawara H., Tanaka T.;
RT   "Human butyrylcholinesterase L330I mutation belongs to a fluoride-resistant
RT   gene, by expression in human fetal kidney cells.";
RL   Biochem. Biophys. Res. Commun. 240:372-375(1997).
RN   [36]
RP   VARIANTS BCHED ILE-32 DEL; MET-52; SER-128; PRO-278; ARG-295; ILE-358;
RP   ARG-393; SER-446; CYS-543 AND THR-567.
RX   PubMed=9191541;
RA   Maekawa M., Sudo K., Dey D.C., Ishikawa J., Izumi M., Kotani K., Kanno T.;
RT   "Genetic mutations of butyrylcholine esterase identified from phenotypic
RT   abnormalities in Japan.";
RL   Clin. Chem. 43:924-929(1997).
RN   [37]
RP   VARIANTS BCHED GLY-98 AND ASP-143.
RX   PubMed=9110359; DOI=10.1097/00008571-199702000-00004;
RA   Primo-Parmo S.L., Lightstone H., La Du B.N.;
RT   "Characterization of an unstable variant (BChE115D) of human
RT   butyrylcholinesterase.";
RL   Pharmacogenetics 7:27-34(1997).
RN   [38]
RP   VARIANT BCHED VAL-227.
RX   PubMed=9694584; DOI=10.1016/s0009-8981(98)00058-8;
RA   Sakamoto N., Hidaka K., Fujisawa T., Maeda M., Iuchi I.;
RT   "Identification of a point mutation associated with a silent phenotype of
RT   human serum butyrylcholinesterase - a case of familial cholinesterasemia.";
RL   Clin. Chim. Acta 274:159-166(1998).
RN   [39]
RP   VARIANTS BCHED ILE-358; ARG-393 AND CYS-543.
RX   PubMed=10404729; DOI=10.1016/s0009-8981(99)00030-3;
RA   Asanuma K., Yagihashi A., Uehara N., Kida T., Watanabe N.;
RT   "Three point mutations of human butyrylcholinesterase in a Japanese family
RT   and the alterations of three-dimensional structure.";
RL   Clin. Chim. Acta 283:33-42(1999).
RN   [40]
RP   VARIANTS BCHED GLY-98; HIS-98; MET-271 AND THR-567.
RX   PubMed=11928765; DOI=10.1258/0004563021901775;
RA   Boeck A.T., Fry D.L., Sastre A., Lockridge O.;
RT   "Naturally occurring mutation, Asp70His, in human butyrylcholinesterase.";
RL   Ann. Clin. Biochem. 39:154-156(2002).
RN   [41]
RP   VARIANTS BCHED ILE-56; TYR-124; CYS-414 AND LYS-488.
RX   PubMed=12881446; DOI=10.1373/49.8.1297;
RA   Yen T., Nightingale B.N., Burns J.C., Sullivan D.R., Stewart P.M.;
RT   "Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in
RT   an Australian population.";
RL   Clin. Chem. 49:1297-1308(2003).
RN   [42]
RP   VARIANTS BCHED CYS-414 AND LEU-502.
RX   PubMed=15563885; DOI=10.1016/j.cccn.2004.09.004;
RA   On-Kei Chan A., Lam C.-W., Tong S.-F., Man Tung C., Yung K., Chan Y.-W.,
RA   Au K.-M., Yuen Y.-P., Hung C.-T., Ng K.-P., Shek C.-C.;
RT   "Novel mutations in the BCHE gene in patients with no butyrylcholinesterase
RT   activity.";
RL   Clin. Chim. Acta 351:155-159(2005).
RN   [43]
RP   VARIANT MET-127, AND VARIANTS BCHED GLY-98; ARG-103 AND ASP-118.
RX   PubMed=15781196; DOI=10.1016/j.ymgme.2004.12.005;
RA   Souza R.L., Mikami L.R., Maegawa R.O., Chautard-Freire-Maia E.A.;
RT   "Four new mutations in the BCHE gene of human butyrylcholinesterase in a
RT   Brazilian blood donor sample.";
RL   Mol. Genet. Metab. 84:349-353(2005).
RN   [44]
RP   VARIANT BCHED PRO-335, AND CHARACTERIZATION OF VARIANT BCHED PRO-335.
RX   PubMed=16788378; DOI=10.1097/01.fpc.0000197464.37211.77;
RA   Manoharan I., Wieseler S., Layer P.G., Lockridge O., Boopathy R.;
RT   "Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in
RT   the Vysya community of India.";
RL   Pharmacogenet. Genomics 16:461-468(2006).
RN   [45]
RP   CHARACTERIZATION OF VARIANT MET-127, AND CHARACTERIZATION OF VARIANTS BCHED
RP   ARG-103 AND ASP-118.
RX   PubMed=17700357; DOI=10.1097/01.fpc.0000236333.49422.86;
RA   Mikami L.R., Wieseler S., Souza R.L., Schopfer L.M., Lockridge O.,
RA   Chautard-Freire-Maia E.A.;
RT   "Expression of three naturally occurring genetic variants (G75R, E90D,
RT   I99M) of the BCHE gene of human butyrylcholinesterase.";
RL   Pharmacogenet. Genomics 17:681-685(2007).
RN   [46]
RP   VARIANT BCHED ASP-356.
RX   PubMed=18075469; DOI=10.1097/fpc.0b013e3282f06646;
RA   Gaetke M.R., Bundgaard J.R., Viby-Mogensen J.;
RT   "Two novel mutations in the BCHE gene in patients with prolonged duration
RT   of action of mivacurium or succinylcholine during anaesthesia.";
RL   Pharmacogenet. Genomics 17:995-999(2007).
RN   [47]
RP   VARIANT BCHED CYS-361, VARIANTS ARG-40; MET-322 AND TRP-498,
RP   CHARACTERIZATION OF VARIANT BCHED CYS-361, AND CHARACTERIZATION OF VARIANTS
RP   ARG-40; MET-322 AND TRP-498.
RX   PubMed=18300943; DOI=10.1097/fpc.0b013e3282f5107e;
RA   Mikami L.R., Wieseler S., Souza R.L., Schopfer L.M., Nachon F.,
RA   Lockridge O., Chautard-Freire-Maia E.A.;
RT   "Five new naturally occurring mutations of the BCHE gene and frequencies of
RT   12 butyrylcholinesterase alleles in a Brazilian population.";
RL   Pharmacogenet. Genomics 18:213-218(2008).
RN   [48]
RP   VARIANTS BCHED VAL-62 AND GLY-98, AND CHARACTERIZATION OF VARIANTS BCHED
RP   VAL-62 AND GLY-98.
RX   PubMed=25264279; DOI=10.1016/j.bcp.2014.09.014;
RA   Delacour H., Lushchekina S., Mabboux I., Ceppa F., Masson P.,
RA   Schopfer L.M., Lockridge O.;
RT   "Characterization of a novel butyrylcholinesterase point mutation
RT   (p.Ala34Val), 'silent' with mivacurium.";
RL   Biochem. Pharmacol. 92:476-483(2014).
CC   -!- FUNCTION: Esterase with broad substrate specificity. Contributes to the
CC       inactivation of the neurotransmitter acetylcholine. Can degrade
CC       neurotoxic organophosphate esters. {ECO:0000269|PubMed:19452557,
CC       ECO:0000269|PubMed:19542320}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an acylcholine + H2O = a carboxylate + choline + H(+);
CC         Xref=Rhea:RHEA:21964, ChEBI:CHEBI:15354, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29067, ChEBI:CHEBI:35287; EC=3.1.1.8;
CC         Evidence={ECO:0000269|PubMed:19368529, ECO:0000269|PubMed:19452557};
CC   -!- ACTIVITY REGULATION: Inhibited by mercury. Inhibited by Tabun. Tabun
CC       forms a covalent adduct with Ser-226 that becomes irreversible upon
CC       aging. {ECO:0000269|PubMed:17355286, ECO:0000269|PubMed:18975951,
CC       ECO:0000269|PubMed:19368529}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=18.0 uM for butyrylthiocholine (at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:25054547};
CC   -!- SUBUNIT: Homotetramer; disulfide-linked. Dimer of dimers.
CC       {ECO:0000269|PubMed:12869558, ECO:0000269|PubMed:15667209,
CC       ECO:0000269|PubMed:17355286, ECO:0000269|PubMed:17768338,
CC       ECO:0000269|PubMed:18975951, ECO:0000269|PubMed:19368529,
CC       ECO:0000269|PubMed:19542320, ECO:0000269|PubMed:3115973}.
CC   -!- INTERACTION:
CC       P06276; P54252: ATXN3; NbExp=3; IntAct=EBI-7936069, EBI-946046;
CC       P06276; P46379-2: BAG6; NbExp=3; IntAct=EBI-7936069, EBI-10988864;
CC       P06276; P06276: BCHE; NbExp=8; IntAct=EBI-7936069, EBI-7936069;
CC       P06276; P55212: CASP6; NbExp=3; IntAct=EBI-7936069, EBI-718729;
CC       P06276; O75190-2: DNAJB6; NbExp=3; IntAct=EBI-7936069, EBI-12593112;
CC       P06276; O14901: KLF11; NbExp=3; IntAct=EBI-7936069, EBI-948266;
CC       P06276; P13473-2: LAMP2; NbExp=3; IntAct=EBI-7936069, EBI-21591415;
CC       P06276; O75400-2: PRPF40A; NbExp=3; IntAct=EBI-7936069, EBI-5280197;
CC       P06276; P62826: RAN; NbExp=3; IntAct=EBI-7936069, EBI-286642;
CC       P06276; P67812: SEC11A; NbExp=3; IntAct=EBI-7936069, EBI-1042500;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:19368529,
CC       ECO:0000269|PubMed:19542320}.
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma (at protein level).
CC       Present in most cells except erythrocytes.
CC       {ECO:0000269|PubMed:19368529, ECO:0000269|PubMed:19542320}.
CC   -!- PTM: N-glycosylated. No other PTM detected (PubMed:20946535). The major
CC       N-glycan structures are of the complex diantennary type with 1 and 2 N-
CC       acetylneuraminic acid molecules (Neu5Ac) making up approximately 33%
CC       and 47% of the total N-glycans, respectively. Only low amounts of
CC       fucosylated diantennary N-glycans are detected (approximately 2%).
CC       Triantennary N-glycans with or without fucose amount to approximately
CC       13%, whereas 5% of the total N-glycans are of the oligomannosidic or
CC       hybrid type. {ECO:0000269|PubMed:12869558, ECO:0000269|PubMed:14760718,
CC       ECO:0000269|PubMed:15667209, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:17355286, ECO:0000269|PubMed:17768338,
CC       ECO:0000269|PubMed:18203274, ECO:0000269|PubMed:18975951,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19368529, ECO:0000269|PubMed:20946535}.
CC   -!- DISEASE: Butyrylcholinesterase deficiency (BCHED) [MIM:617936]: An
CC       autosomal recessive metabolic condition characterized by increased
CC       sensitivity to certain anesthetic drugs, including the muscle relaxants
CC       succinylcholine or mivacurium. BCHED results in slower hydrolysis of
CC       these drugs and, consequently, a prolonged neuromuscular block, leading
CC       to apnea. The duration of the prolonged apnea varies significantly
CC       depending on the extent of the enzyme deficiency.
CC       {ECO:0000269|PubMed:10404729, ECO:0000269|PubMed:11928765,
CC       ECO:0000269|PubMed:12881446, ECO:0000269|PubMed:1306123,
CC       ECO:0000269|PubMed:1349196, ECO:0000269|PubMed:1415224,
CC       ECO:0000269|PubMed:15563885, ECO:0000269|PubMed:15781196,
CC       ECO:0000269|PubMed:1611188, ECO:0000269|PubMed:16788378,
CC       ECO:0000269|PubMed:17700357, ECO:0000269|PubMed:18075469,
CC       ECO:0000269|PubMed:18300943, ECO:0000269|PubMed:25054547,
CC       ECO:0000269|PubMed:25264279, ECO:0000269|PubMed:2915989,
CC       ECO:0000269|PubMed:7634491, ECO:0000269|PubMed:8554068,
CC       ECO:0000269|PubMed:8680411, ECO:0000269|PubMed:9110359,
CC       ECO:0000269|PubMed:9191541, ECO:0000269|PubMed:9388484,
CC       ECO:0000269|PubMed:9543549, ECO:0000269|PubMed:9694584}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the type-B carboxylesterase/lipase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M32391; AAA99296.1; -; Genomic_DNA.
DR   EMBL; M32389; AAA99296.1; JOINED; Genomic_DNA.
DR   EMBL; M32390; AAA99296.1; JOINED; Genomic_DNA.
DR   EMBL; M16541; AAA98113.1; -; mRNA.
DR   EMBL; M16474; AAA52015.1; -; mRNA.
DR   EMBL; AK292063; BAF84752.1; -; mRNA.
DR   EMBL; BC018141; AAH18141.1; -; mRNA.
DR   CCDS; CCDS3198.1; -.
DR   PIR; A33769; ACHU.
DR   RefSeq; NP_000046.1; NM_000055.3.
DR   PDB; 1EHO; Model; -; A=30-560.
DR   PDB; 1EHQ; Model; -; A=30-560.
DR   PDB; 1KCJ; Model; -; A=30-560.
DR   PDB; 1P0I; X-ray; 2.00 A; A=29-557.
DR   PDB; 1P0M; X-ray; 2.38 A; A=29-557.
DR   PDB; 1P0P; X-ray; 2.30 A; A=29-557.
DR   PDB; 1P0Q; X-ray; 2.43 A; A=29-557.
DR   PDB; 1XLU; X-ray; 2.20 A; A=29-557.
DR   PDB; 1XLV; X-ray; 2.25 A; A=29-557.
DR   PDB; 1XLW; X-ray; 2.10 A; A=29-557.
DR   PDB; 2J4C; X-ray; 2.75 A; A=29-557.
DR   PDB; 2PM8; X-ray; 2.80 A; A/B=29-602.
DR   PDB; 2WID; X-ray; 2.30 A; A=29-557.
DR   PDB; 2WIF; X-ray; 2.25 A; A=29-557.
DR   PDB; 2WIG; X-ray; 2.15 A; A=29-557.
DR   PDB; 2WIJ; X-ray; 2.10 A; A=29-557.
DR   PDB; 2WIK; X-ray; 2.10 A; A=29-557.
DR   PDB; 2WIL; X-ray; 3.10 A; A/B=29-557.
DR   PDB; 2WSL; X-ray; 2.00 A; A=29-557.
DR   PDB; 2XMB; X-ray; 2.10 A; A=29-557.
DR   PDB; 2XMC; X-ray; 2.40 A; A=29-557.
DR   PDB; 2XMD; X-ray; 2.30 A; A=29-557.
DR   PDB; 2XMG; X-ray; 2.70 A; A=29-557.
DR   PDB; 2XQF; X-ray; 2.10 A; A=31-557.
DR   PDB; 2XQG; X-ray; 2.30 A; A=31-557.
DR   PDB; 2XQI; X-ray; 2.60 A; A=31-557.
DR   PDB; 2XQJ; X-ray; 2.40 A; A=31-557.
DR   PDB; 2XQK; X-ray; 2.40 A; A=31-557.
DR   PDB; 2Y1K; X-ray; 2.50 A; A=29-557.
DR   PDB; 3DJY; X-ray; 2.10 A; A=29-557.
DR   PDB; 3DKK; X-ray; 2.31 A; A=29-557.
DR   PDB; 3O9M; X-ray; 2.98 A; A/B=29-602.
DR   PDB; 4AQD; X-ray; 2.50 A; A/B=29-557.
DR   PDB; 4AXB; X-ray; 2.40 A; A=31-557.
DR   PDB; 4B0O; X-ray; 2.35 A; A=29-557.
DR   PDB; 4B0P; X-ray; 2.50 A; A=29-557.
DR   PDB; 4BBZ; X-ray; 2.70 A; A=29-557.
DR   PDB; 4BDS; X-ray; 2.10 A; A=29-557.
DR   PDB; 4TPK; X-ray; 2.70 A; A/B=1-602.
DR   PDB; 4XII; X-ray; 2.70 A; A/B=29-572.
DR   PDB; 5DYT; X-ray; 2.55 A; A/B=28-557.
DR   PDB; 5DYW; X-ray; 2.50 A; A/B=28-557.
DR   PDB; 5DYY; X-ray; 2.65 A; A/B=28-557.
DR   PDB; 5K5E; X-ray; 2.80 A; A/B=29-557.
DR   PDB; 5LKR; X-ray; 2.52 A; A/B=29-602.
DR   PDB; 5NN0; X-ray; 2.10 A; A=29-557.
DR   PDB; 6EMI; X-ray; 2.48 A; A/B=29-557.
DR   PDB; 6EP4; X-ray; 2.30 A; A=29-557.
DR   PDB; 6EQP; X-ray; 2.35 A; A=29-557.
DR   PDB; 6EQQ; X-ray; 2.40 A; A=29-557.
DR   PDB; 6ESJ; X-ray; 2.98 A; A/B=29-557.
DR   PDB; 6ESY; X-ray; 2.80 A; A/B=29-557.
DR   PDB; 6EUL; X-ray; 2.60 A; A=31-558.
DR   PDB; 6EYF; X-ray; 2.60 A; A=31-557.
DR   PDB; 6EZ2; X-ray; 2.70 A; A/B=31-557.
DR   PDB; 6F7Q; X-ray; 2.60 A; A/B=29-557.
DR   PDB; 6I0B; X-ray; 2.38 A; A=29-557.
DR   PDB; 6I0C; X-ray; 2.67 A; A=29-557.
DR   PDB; 6I2T; EM; 5.70 A; A/B/C/D=29-602.
DR   PDB; 6QAA; X-ray; 1.90 A; A=1-557.
DR   PDB; 6QAB; X-ray; 2.49 A; A=1-557.
DR   PDB; 6QAC; X-ray; 2.77 A; A=1-557.
DR   PDB; 6QAD; X-ray; 2.50 A; A=1-557.
DR   PDB; 6QAE; X-ray; 2.49 A; A=1-557.
DR   PDB; 6R6V; X-ray; 2.50 A; A=32-557.
DR   PDB; 6R6W; X-ray; 2.47 A; A=32-557.
DR   PDB; 6RUA; X-ray; 2.75 A; A/B=29-602.
DR   PDB; 6SAM; X-ray; 2.50 A; A=29-557.
DR   PDB; 6T9P; X-ray; 2.70 A; A=29-557.
DR   PDB; 6T9S; X-ray; 2.70 A; A=29-557.
DR   PDB; 6XTA; X-ray; 2.50 A; A=29-557.
DR   PDBsum; 1EHO; -.
DR   PDBsum; 1EHQ; -.
DR   PDBsum; 1KCJ; -.
DR   PDBsum; 1P0I; -.
DR   PDBsum; 1P0M; -.
DR   PDBsum; 1P0P; -.
DR   PDBsum; 1P0Q; -.
DR   PDBsum; 1XLU; -.
DR   PDBsum; 1XLV; -.
DR   PDBsum; 1XLW; -.
DR   PDBsum; 2J4C; -.
DR   PDBsum; 2PM8; -.
DR   PDBsum; 2WID; -.
DR   PDBsum; 2WIF; -.
DR   PDBsum; 2WIG; -.
DR   PDBsum; 2WIJ; -.
DR   PDBsum; 2WIK; -.
DR   PDBsum; 2WIL; -.
DR   PDBsum; 2WSL; -.
DR   PDBsum; 2XMB; -.
DR   PDBsum; 2XMC; -.
DR   PDBsum; 2XMD; -.
DR   PDBsum; 2XMG; -.
DR   PDBsum; 2XQF; -.
DR   PDBsum; 2XQG; -.
DR   PDBsum; 2XQI; -.
DR   PDBsum; 2XQJ; -.
DR   PDBsum; 2XQK; -.
DR   PDBsum; 2Y1K; -.
DR   PDBsum; 3DJY; -.
DR   PDBsum; 3DKK; -.
DR   PDBsum; 3O9M; -.
DR   PDBsum; 4AQD; -.
DR   PDBsum; 4AXB; -.
DR   PDBsum; 4B0O; -.
DR   PDBsum; 4B0P; -.
DR   PDBsum; 4BBZ; -.
DR   PDBsum; 4BDS; -.
DR   PDBsum; 4TPK; -.
DR   PDBsum; 4XII; -.
DR   PDBsum; 5DYT; -.
DR   PDBsum; 5DYW; -.
DR   PDBsum; 5DYY; -.
DR   PDBsum; 5K5E; -.
DR   PDBsum; 5LKR; -.
DR   PDBsum; 5NN0; -.
DR   PDBsum; 6EMI; -.
DR   PDBsum; 6EP4; -.
DR   PDBsum; 6EQP; -.
DR   PDBsum; 6EQQ; -.
DR   PDBsum; 6ESJ; -.
DR   PDBsum; 6ESY; -.
DR   PDBsum; 6EUL; -.
DR   PDBsum; 6EYF; -.
DR   PDBsum; 6EZ2; -.
DR   PDBsum; 6F7Q; -.
DR   PDBsum; 6I0B; -.
DR   PDBsum; 6I0C; -.
DR   PDBsum; 6I2T; -.
DR   PDBsum; 6QAA; -.
DR   PDBsum; 6QAB; -.
DR   PDBsum; 6QAC; -.
DR   PDBsum; 6QAD; -.
DR   PDBsum; 6QAE; -.
DR   PDBsum; 6R6V; -.
DR   PDBsum; 6R6W; -.
DR   PDBsum; 6RUA; -.
DR   PDBsum; 6SAM; -.
DR   PDBsum; 6T9P; -.
DR   PDBsum; 6T9S; -.
DR   PDBsum; 6XTA; -.
DR   SMR; P06276; -.
DR   BioGRID; 107064; 43.
DR   DIP; DIP-46476N; -.
DR   IntAct; P06276; 39.
DR   MINT; P06276; -.
DR   STRING; 9606.ENSP00000264381; -.
DR   BindingDB; P06276; -.
DR   ChEMBL; CHEMBL1914; -.
DR   DrugBank; DB08200; (1R)-menthyl hexyl phosphonate group.
DR   DrugBank; DB08201; (1S)-menthyl hexyl phosphonate group.
DR   DrugBank; DB03814; 2-(N-morpholino)ethanesulfonic acid.
DR   DrugBank; DB07940; 9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE.
DR   DrugBank; DB03672; 9-N-Phenylmethylamino-Tacrine.
DR   DrugBank; DB08897; Aclidinium.
DR   DrugBank; DB01122; Ambenonium.
DR   DrugBank; DB06692; Aprotinin.
DR   DrugBank; DB01408; Bambuterol.
DR   DrugBank; DB00868; Benzonatate.
DR   DrugBank; DB11148; Butamben.
DR   DrugBank; DB03568; Butyric Acid.
DR   DrugBank; DB04250; Butyrylthiocholine.
DR   DrugBank; DB06774; Capsaicin.
DR   DrugBank; DB01161; Chloroprocaine.
DR   DrugBank; DB00856; Chlorphenesin.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB00122; Choline.
DR   DrugBank; DB14006; Choline salicylate.
DR   DrugBank; DB00527; Cinchocaine.
DR   DrugBank; DB00515; Cisplatin.
DR   DrugBank; DB04920; Clevidipine.
DR   DrugBank; DB00907; Cocaine.
DR   DrugBank; DB00979; Cyclopentolate.
DR   DrugBank; DB01245; Decamethonium.
DR   DrugBank; DB00944; Demecarium.
DR   DrugBank; DB11397; Dichlorvos.
DR   DrugBank; DB02811; Diethyl phosphonate.
DR   DrugBank; DB00711; Diethylcarbamazine.
DR   DrugBank; DB00449; Dipivefrin.
DR   DrugBank; DB07681; DODECANESULFONATE ION.
DR   DrugBank; DB00843; Donepezil.
DR   DrugBank; DB01135; Doxacurium.
DR   DrugBank; DB01057; Echothiophate.
DR   DrugBank; DB01010; Edrophonium.
DR   DrugBank; DB01364; Ephedrine.
DR   DrugBank; DB03822; Ethyl dihydrogen phosphate.
DR   DrugBank; DB08658; Ethyl hydrogen diethylamidophosphate.
DR   DrugBank; DB00674; Galantamine.
DR   DrugBank; DB06756; Glycine betaine.
DR   DrugBank; DB00941; Hexafluronium.
DR   DrugBank; DB00762; Irinotecan.
DR   DrugBank; DB00677; Isoflurophate.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB00772; Malathion.
DR   DrugBank; DB00888; Mechlorethamine.
DR   DrugBank; DB00358; Mefloquine.
DR   DrugBank; DB02845; Methylphosphinic Acid.
DR   DrugBank; DB08893; Mirabegron.
DR   DrugBank; DB01226; Mivacurium.
DR   DrugBank; DB09205; Moxisylyte.
DR   DrugBank; DB01400; Neostigmine.
DR   DrugBank; DB00585; Nizatidine.
DR   DrugBank; DB00892; Oxybuprocaine.
DR   DrugBank; DB01337; Pancuronium.
DR   DrugBank; DB00082; Pegvisomant.
DR   DrugBank; DB00183; Pentagastrin.
DR   DrugBank; DB00790; Perindopril.
DR   DrugBank; DB04892; Phenserine.
DR   DrugBank; DB03976; Phosphorylisopropane.
DR   DrugBank; DB01338; Pipecuronium.
DR   DrugBank; DB00733; Pralidoxime.
DR   DrugBank; DB01035; Procainamide.
DR   DrugBank; DB00721; Procaine.
DR   DrugBank; DB00392; Profenamine.
DR   DrugBank; DB09288; Propacetamol.
DR   DrugBank; DB00545; Pyridostigmine.
DR   DrugBank; DB00178; Ramipril.
DR   DrugBank; DB05386; Regramostim.
DR   DrugBank; DB00989; Rivastigmine.
DR   DrugBank; DB05875; Sar9, Met (O2)11-Substance P.
DR   DrugBank; DB00202; Succinylcholine.
DR   DrugBank; DB00391; Sulpiride.
DR   DrugBank; DB00382; Tacrine.
DR   DrugBank; DB00871; Terbutaline.
DR   DrugBank; DB04572; Thiotepa.
DR   DrugBank; DB14031; Tretamine.
DR   DrugBank; DB00620; Triamcinolone.
DR   DrugBank; DB00508; Triflupromazine.
DR   DrugBank; DB01116; Trimethaphan.
DR   DrugBank; DB01199; Tubocurarine.
DR   DrugCentral; P06276; -.
DR   GuidetoPHARMACOLOGY; 2471; -.
DR   ESTHER; human-BCHE; BCHE.
DR   MEROPS; S09.980; -.
DR   GlyConnect; 1109; 12 N-Linked glycans (4 sites).
DR   GlyGen; P06276; 12 sites.
DR   iPTMnet; P06276; -.
DR   PhosphoSitePlus; P06276; -.
DR   BioMuta; BCHE; -.
DR   DMDM; 116353; -.
DR   CPTAC; non-CPTAC-2645; -.
DR   EPD; P06276; -.
DR   jPOST; P06276; -.
DR   MassIVE; P06276; -.
DR   MaxQB; P06276; -.
DR   PaxDb; P06276; -.
DR   PeptideAtlas; P06276; -.
DR   PRIDE; P06276; -.
DR   ProteomicsDB; 51880; -.
DR   ABCD; P06276; 4 sequenced antibodies.
DR   Antibodypedia; 879; 440 antibodies.
DR   DNASU; 590; -.
DR   Ensembl; ENST00000264381; ENSP00000264381; ENSG00000114200.
DR   GeneID; 590; -.
DR   KEGG; hsa:590; -.
DR   UCSC; uc003fem.5; human.
DR   CTD; 590; -.
DR   DisGeNET; 590; -.
DR   GeneCards; BCHE; -.
DR   HGNC; HGNC:983; BCHE.
DR   HPA; ENSG00000114200; Tissue enriched (liver).
DR   MalaCards; BCHE; -.
DR   MIM; 177400; gene.
DR   MIM; 617936; phenotype.
DR   neXtProt; NX_P06276; -.
DR   OpenTargets; ENSG00000114200; -.
DR   Orphanet; 132; Butyrylcholinesterase deficiency.
DR   Orphanet; 413693; Curariform drugs toxicity.
DR   PharmGKB; PA25294; -.
DR   VEuPathDB; HostDB:ENSG00000114200.9; -.
DR   eggNOG; KOG4389; Eukaryota.
DR   GeneTree; ENSGT00940000157023; -.
DR   InParanoid; P06276; -.
DR   OMA; EMRYICP; -.
DR   OrthoDB; 754103at2759; -.
DR   PhylomeDB; P06276; -.
DR   TreeFam; TF315470; -.
DR   BRENDA; 3.1.1.8; 2681.
DR   PathwayCommons; P06276; -.
DR   Reactome; R-HSA-112311; Neurotransmitter clearance.
DR   Reactome; R-HSA-1483191; Synthesis of PC.
DR   Reactome; R-HSA-422085; Synthesis, secretion, and deacylation of Ghrelin.
DR   SABIO-RK; P06276; -.
DR   SIGNOR; P06276; -.
DR   BioGRID-ORCS; 590; 9 hits in 996 CRISPR screens.
DR   ChiTaRS; BCHE; human.
DR   EvolutionaryTrace; P06276; -.
DR   GeneWiki; Butyrylcholinesterase; -.
DR   GenomeRNAi; 590; -.
DR   Pharos; P06276; Tclin.
DR   PRO; PR:P06276; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P06276; protein.
DR   Bgee; ENSG00000114200; Expressed in parietal pleura and 197 other tissues.
DR   ExpressionAtlas; P06276; baseline and differential.
DR   Genevisible; P06276; HS.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IEA:Ensembl.
DR   GO; GO:0005641; C:nuclear envelope lumen; IEA:Ensembl.
DR   GO; GO:0003990; F:acetylcholinesterase activity; ISS:UniProtKB.
DR   GO; GO:0001540; F:amyloid-beta binding; NAS:UniProtKB.
DR   GO; GO:0003824; F:catalytic activity; NAS:UniProtKB.
DR   GO; GO:0033265; F:choline binding; IEA:Ensembl.
DR   GO; GO:0004104; F:cholinesterase activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; NAS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019695; P:choline metabolic process; IEA:Ensembl.
DR   GO; GO:0050783; P:cocaine metabolic process; TAS:UniProtKB.
DR   GO; GO:0007612; P:learning; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0050805; P:negative regulation of synaptic transmission; IEA:Ensembl.
DR   GO; GO:0014016; P:neuroblast differentiation; IEA:Ensembl.
DR   GO; GO:0043279; P:response to alkaloid; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0051593; P:response to folic acid; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   Gene3D; 3.40.50.1820; -; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR014788; AChE_tetra.
DR   InterPro; IPR002018; CarbesteraseB.
DR   InterPro; IPR019826; Carboxylesterase_B_AS.
DR   InterPro; IPR019819; Carboxylesterase_B_CS.
DR   InterPro; IPR000997; Cholinesterase.
DR   Pfam; PF08674; AChE_tetra; 1.
DR   Pfam; PF00135; COesterase; 1.
DR   PRINTS; PR00878; CHOLNESTRASE.
DR   SUPFAM; SSF53474; SSF53474; 1.
DR   PROSITE; PS00122; CARBOXYLESTERASE_B_1; 1.
DR   PROSITE; PS00941; CARBOXYLESTERASE_B_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Direct protein sequencing; Disease variant; Disulfide bond;
KW   Glycoprotein; Hydrolase; Phosphoprotein; Reference proteome; Secreted;
KW   Serine esterase; Sialic acid; Signal.
FT   SIGNAL          1..28
FT                   /evidence="ECO:0000269|PubMed:20946535,
FT                   ECO:0000269|PubMed:3542989"
FT   CHAIN           29..602
FT                   /note="Cholinesterase"
FT                   /id="PRO_0000008613"
FT   REGION          144..145
FT                   /note="Substrate binding"
FT   ACT_SITE        226
FT                   /note="Acyl-ester intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10039,
FT                   ECO:0000269|PubMed:12869558"
FT   ACT_SITE        353
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000269|PubMed:12869558"
FT   ACT_SITE        466
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000269|PubMed:12869558"
FT   BINDING         110
FT                   /note="Tacrine"
FT                   /evidence="ECO:0007744|PDB:4BDS"
FT   BINDING         466
FT                   /note="Tacrine; via carbonyl oxygen"
FT                   /evidence="ECO:0007744|PDB:4BDS"
FT   MOD_RES         226
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22444575"
FT   CARBOHYD        45
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:18203274"
FT   CARBOHYD        85
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12869558,
FT                   ECO:0000269|PubMed:15667209, ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:17355286, ECO:0000269|PubMed:17768338,
FT                   ECO:0000269|PubMed:18203274, ECO:0000269|PubMed:18975951,
FT                   ECO:0000269|PubMed:19368529, ECO:0000269|PubMed:23679855"
FT   CARBOHYD        134
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12869558,
FT                   ECO:0000269|PubMed:15667209, ECO:0000269|PubMed:17355286,
FT                   ECO:0000269|PubMed:17768338, ECO:0000269|PubMed:18203274,
FT                   ECO:0000269|PubMed:18975951, ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:19368529, ECO:0000269|PubMed:23679855"
FT   CARBOHYD        269
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12869558,
FT                   ECO:0000269|PubMed:15667209, ECO:0000269|PubMed:17355286,
FT                   ECO:0000269|PubMed:18203274, ECO:0000269|PubMed:19368529,
FT                   ECO:0000269|PubMed:23679855"
FT   CARBOHYD        284
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18203274,
FT                   ECO:0000269|PubMed:18975951, ECO:0000269|PubMed:19139490,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19368529,
FT                   ECO:0000269|PubMed:23679855"
FT   CARBOHYD        369
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12869558,
FT                   ECO:0000269|PubMed:15667209, ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:17355286, ECO:0000269|PubMed:17768338,
FT                   ECO:0000269|PubMed:18203274, ECO:0000269|PubMed:18975951,
FT                   ECO:0000269|PubMed:19368529, ECO:0000269|PubMed:23679855"
FT   CARBOHYD        483
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:18203274"
FT   CARBOHYD        509
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14760718,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:3542989"
FT   CARBOHYD        513
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12869558,
FT                   ECO:0000269|PubMed:15667209, ECO:0000269|PubMed:17355286,
FT                   ECO:0000269|PubMed:17768338, ECO:0000269|PubMed:18975951,
FT                   ECO:0000269|PubMed:19368529, ECO:0000269|PubMed:23679855"
FT   CARBOHYD        514
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14760718,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:3542989"
FT   DISULFID        93..120
FT   DISULFID        280..291
FT   DISULFID        428..547
FT   DISULFID        599
FT                   /note="Interchain"
FT   VARIANT         32
FT                   /note="Missing (in BCHED)"
FT                   /evidence="ECO:0000269|PubMed:9191541"
FT                   /id="VAR_040011"
FT   VARIANT         40
FT                   /note="K -> R (does not affect enzymatic activity;
FT                   dbSNP:rs116047990)"
FT                   /evidence="ECO:0000269|PubMed:18300943"
FT                   /id="VAR_072094"
FT   VARIANT         52
FT                   /note="T -> M (in BCHED; dbSNP:rs56309853)"
FT                   /evidence="ECO:0000269|PubMed:9191541"
FT                   /id="VAR_040012"
FT   VARIANT         56
FT                   /note="F -> I (in BCHED; dbSNP:rs531738678)"
FT                   /evidence="ECO:0000269|PubMed:12881446"
FT                   /id="VAR_040013"
FT   VARIANT         61
FT                   /note="Y -> C (in BCHED; enzymatically inactive in the
FT                   plasma; dbSNP:rs116097205)"
FT                   /evidence="ECO:0000269|PubMed:8554068"
FT                   /id="VAR_040014"
FT   VARIANT         62
FT                   /note="A -> V (in BCHED; reduced enzyme activity with
FT                   butyrylthiocholine as substrate; inactive with
FT                   butyrylthiocholine as substrate in the presence of G-98; 2-
FT                   fold lower affinity for butyrylthiocholine; 10-fold lower
FT                   affinity for butyrylthiocholine in the presence of G-98;
FT                   dbSNP:rs1553778274)"
FT                   /evidence="ECO:0000269|PubMed:25264279"
FT                   /id="VAR_072730"
FT   VARIANT         65
FT                   /note="P -> S (in BCHED; seems to cause reduced expression
FT                   of the protein; dbSNP:rs148170012)"
FT                   /evidence="ECO:0000269|PubMed:8554068"
FT                   /id="VAR_040015"
FT   VARIANT         98
FT                   /note="D -> G (in BCHED; atypical form; reduced enzyme
FT                   activity with butyrylthiocholine as substrate; inactive
FT                   with butyrylthiocholine as substrate in the presence of V-
FT                   62; 2-fold lower affinity for butyrylthiocholine; 10-fold
FT                   lower affinity for butyrylthiocholine in the presence of V-
FT                   62 or at homozygosity; dbSNP:rs1799807)"
FT                   /evidence="ECO:0000269|PubMed:11928765,
FT                   ECO:0000269|PubMed:1306123, ECO:0000269|PubMed:15781196,
FT                   ECO:0000269|PubMed:25264279, ECO:0000269|PubMed:2915989,
FT                   ECO:0000269|PubMed:9110359"
FT                   /id="VAR_002360"
FT   VARIANT         98
FT                   /note="D -> H (in BCHED)"
FT                   /evidence="ECO:0000269|PubMed:11928765"
FT                   /id="VAR_040016"
FT   VARIANT         103
FT                   /note="G -> R (in BCHED; reduced enzyme activity;
FT                   dbSNP:rs979653503)"
FT                   /evidence="ECO:0000269|PubMed:15781196,
FT                   ECO:0000269|PubMed:17700357"
FT                   /id="VAR_072095"
FT   VARIANT         118
FT                   /note="E -> D (in BCHED; the mutant undergoes rapid
FT                   degradation)"
FT                   /evidence="ECO:0000269|PubMed:15781196,
FT                   ECO:0000269|PubMed:17700357"
FT                   /id="VAR_072096"
FT   VARIANT         124
FT                   /note="N -> Y (in BCHED; dbSNP:rs1339128583)"
FT                   /evidence="ECO:0000269|PubMed:12881446"
FT                   /id="VAR_040017"
FT   VARIANT         127
FT                   /note="I -> M (does not affect enzyme activity;
FT                   dbSNP:rs755600722)"
FT                   /evidence="ECO:0000269|PubMed:15781196,
FT                   ECO:0000269|PubMed:17700357"
FT                   /id="VAR_072097"
FT   VARIANT         128
FT                   /note="P -> S (in BCHED; dbSNP:rs3732880)"
FT                   /evidence="ECO:0000269|PubMed:9191541"
FT                   /id="VAR_040018"
FT   VARIANT         143
FT                   /note="G -> D (in BCHED; dbSNP:rs201820739)"
FT                   /evidence="ECO:0000269|PubMed:9110359"
FT                   /id="VAR_040019"
FT   VARIANT         153
FT                   /note="L -> F (in BCHED; seems to cause reduced expression
FT                   of the protein; dbSNP:rs747598704)"
FT                   /evidence="ECO:0000269|PubMed:8554068"
FT                   /id="VAR_040020"
FT   VARIANT         156
FT                   /note="Y -> C (in BCHED; dbSNP:rs121918558)"
FT                   /evidence="ECO:0000269|PubMed:9543549"
FT                   /id="VAR_040021"
FT   VARIANT         170
FT                   /note="V -> M (in BCHED; allele H variant;
FT                   dbSNP:rs527843566)"
FT                   /evidence="ECO:0000269|PubMed:1306123"
FT                   /id="VAR_040022"
FT   VARIANT         198
FT                   /note="D -> E (in BCHED; seems to cause reduced expression
FT                   of the protein; dbSNP:rs781368801)"
FT                   /evidence="ECO:0000269|PubMed:8554068"
FT                   /id="VAR_040023"
FT   VARIANT         226
FT                   /note="S -> G (in BCHED; enzymatically inactive in the
FT                   plasma; dbSNP:rs370077923)"
FT                   /evidence="ECO:0000269|PubMed:8554068"
FT                   /id="VAR_040024"
FT   VARIANT         227
FT                   /note="A -> V (in BCHED)"
FT                   /evidence="ECO:0000269|PubMed:9694584"
FT                   /id="VAR_040025"
FT   VARIANT         229
FT                   /note="A -> T (in BCHED; enzymatically inactive in the
FT                   plasma)"
FT                   /evidence="ECO:0000269|PubMed:8554068"
FT                   /id="VAR_040026"
FT   VARIANT         232
FT                   /note="V -> D (in BCHED)"
FT                   /evidence="ECO:0000269|PubMed:25054547"
FT                   /id="VAR_072098"
FT   VARIANT         271
FT                   /note="T -> M (in BCHED; allele fluoride-1;
FT                   dbSNP:rs28933389)"
FT                   /evidence="ECO:0000269|PubMed:11928765,
FT                   ECO:0000269|PubMed:1415224"
FT                   /id="VAR_040027"
FT   VARIANT         278
FT                   /note="T -> P (in BCHED; dbSNP:rs892642457)"
FT                   /evidence="ECO:0000269|PubMed:7634491,
FT                   ECO:0000269|PubMed:9191541"
FT                   /id="VAR_040028"
FT   VARIANT         283
FT                   /note="E -> D (in dbSNP:rs16849700)"
FT                   /id="VAR_040029"
FT   VARIANT         295
FT                   /note="K -> R (in BCHED; dbSNP:rs115624085)"
FT                   /evidence="ECO:0000269|PubMed:9191541"
FT                   /id="VAR_040030"
FT   VARIANT         322
FT                   /note="V -> M (does not affect enzymatic activity;
FT                   dbSNP:rs754644618)"
FT                   /evidence="ECO:0000269|PubMed:18300943"
FT                   /id="VAR_072099"
FT   VARIANT         335
FT                   /note="L -> P (in BCHED; expressed at very low level;
FT                   dbSNP:rs104893684)"
FT                   /evidence="ECO:0000269|PubMed:16788378"
FT                   /id="VAR_040031"
FT   VARIANT         356
FT                   /note="A -> D (in BCHED; dbSNP:rs770337031)"
FT                   /evidence="ECO:0000269|PubMed:18075469"
FT                   /id="VAR_040032"
FT   VARIANT         358
FT                   /note="L -> I (in BCHED; BChE variant form; fluoride-
FT                   resistant; dbSNP:rs121918557)"
FT                   /evidence="ECO:0000269|PubMed:10404729,
FT                   ECO:0000269|PubMed:8680411, ECO:0000269|PubMed:9191541,
FT                   ECO:0000269|PubMed:9388484"
FT                   /id="VAR_002362"
FT   VARIANT         361
FT                   /note="G -> C (in BCHED; results in 20% of activity
FT                   compared to wild-type)"
FT                   /evidence="ECO:0000269|PubMed:18300943"
FT                   /id="VAR_072100"
FT   VARIANT         393
FT                   /note="G -> R (in BCHED; dbSNP:rs115129687)"
FT                   /evidence="ECO:0000269|PubMed:10404729,
FT                   ECO:0000269|PubMed:1611188, ECO:0000269|PubMed:7634491,
FT                   ECO:0000269|PubMed:9191541"
FT                   /id="VAR_040033"
FT   VARIANT         414
FT                   /note="R -> C (in BCHED; dbSNP:rs745364489)"
FT                   /evidence="ECO:0000269|PubMed:12881446,
FT                   ECO:0000269|PubMed:15563885"
FT                   /id="VAR_040034"
FT   VARIANT         418
FT                   /note="G -> V (in BCHED; allele fluoride-2;
FT                   dbSNP:rs28933390)"
FT                   /evidence="ECO:0000269|PubMed:1415224"
FT                   /id="VAR_040035"
FT   VARIANT         446
FT                   /note="F -> S (in BCHED)"
FT                   /evidence="ECO:0000269|PubMed:7634491,
FT                   ECO:0000269|PubMed:9191541"
FT                   /id="VAR_040036"
FT   VARIANT         488
FT                   /note="E -> K (in BCHED; dbSNP:rs200998515)"
FT                   /evidence="ECO:0000269|PubMed:12881446"
FT                   /id="VAR_040037"
FT   VARIANT         498
FT                   /note="R -> W (does not affect enzymatic activity;
FT                   dbSNP:rs115017300)"
FT                   /evidence="ECO:0000269|PubMed:18300943"
FT                   /id="VAR_072101"
FT   VARIANT         499
FT                   /note="W -> R (in BCHED; seems to cause reduced expression
FT                   of the protein)"
FT                   /evidence="ECO:0000269|PubMed:8554068"
FT                   /id="VAR_040038"
FT   VARIANT         502
FT                   /note="F -> L (in BCHED; dbSNP:rs769316835)"
FT                   /evidence="ECO:0000269|PubMed:15563885"
FT                   /id="VAR_040039"
FT   VARIANT         525
FT                   /note="E -> V (in BCHED; allele J variant;
FT                   dbSNP:rs121918556)"
FT                   /evidence="ECO:0000269|PubMed:1349196"
FT                   /id="VAR_040040"
FT   VARIANT         543
FT                   /note="R -> C (in BCHED; dbSNP:rs199660374)"
FT                   /evidence="ECO:0000269|PubMed:10404729,
FT                   ECO:0000269|PubMed:7634491, ECO:0000269|PubMed:9191541"
FT                   /id="VAR_040041"
FT   VARIANT         546
FT                   /note="Q -> L (in BCHED; seems to cause reduced expression
FT                   of the protein)"
FT                   /evidence="ECO:0000269|PubMed:8554068"
FT                   /id="VAR_040042"
FT   VARIANT         567
FT                   /note="A -> T (in BCHED; allele K variant; with reduced
FT                   enzyme activity; dbSNP:rs1803274)"
FT                   /evidence="ECO:0000269|PubMed:11928765,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:7634491,
FT                   ECO:0000269|PubMed:9191541"
FT                   /id="VAR_002364"
FT   STRAND          33..36
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          39..42
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          44..48
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          51..60
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           67..69
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          82..85
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           105..108
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          116..118
FT                   /evidence="ECO:0007744|PDB:2XMB"
FT   STRAND          122..130
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          133..141
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   TURN            145..147
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           154..156
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           159..165
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          168..172
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           177..181
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          190..192
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           194..209
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           210..213
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          215..225
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           227..237
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           239..244
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          246..252
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   TURN            258..260
FT                   /evidence="ECO:0007744|PDB:4BDS"
FT   HELIX           264..277
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           285..292
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           297..303
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           304..307
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          308..310
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          324..326
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           331..336
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          345..350
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          352..354
FT                   /evidence="ECO:0007744|PDB:1P0P"
FT   HELIX           355..358
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   TURN            359..361
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          367..369
FT                   /evidence="ECO:0007744|PDB:6EQP"
FT   HELIX           375..385
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          387..389
FT                   /evidence="ECO:0007744|PDB:2WSL"
FT   HELIX           391..401
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   TURN            405..408
FT                   /evidence="ECO:0007744|PDB:2WIK"
FT   HELIX           412..425
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           427..438
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   TURN            439..441
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          444..449
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           460..462
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   TURN            466..469
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           470..473
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           476..478
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           480..482
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           486..505
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   TURN            511..514
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   TURN            523..525
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          527..531
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   STRAND          538..541
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           544..552
FT                   /evidence="ECO:0007744|PDB:6QAA"
FT   HELIX           554..556
FT                   /evidence="ECO:0007744|PDB:6QAA"
SQ   SEQUENCE   602 AA;  68418 MW;  C9836409D9057F27 CRC64;
     MHSKVTIICI RFLFWFLLLC MLIGKSHTED DIIIATKNGK VRGMNLTVFG GTVTAFLGIP
     YAQPPLGRLR FKKPQSLTKW SDIWNATKYA NSCCQNIDQS FPGFHGSEMW NPNTDLSEDC
     LYLNVWIPAP KPKNATVLIW IYGGGFQTGT SSLHVYDGKF LARVERVIVV SMNYRVGALG
     FLALPGNPEA PGNMGLFDQQ LALQWVQKNI AAFGGNPKSV TLFGESAGAA SVSLHLLSPG
     SHSLFTRAIL QSGSFNAPWA VTSLYEARNR TLNLAKLTGC SRENETEIIK CLRNKDPQEI
     LLNEAFVVPY GTPLSVNFGP TVDGDFLTDM PDILLELGQF KKTQILVGVN KDEGTAFLVY
     GAPGFSKDNN SIITRKEFQE GLKIFFPGVS EFGKESILFH YTDWVDDQRP ENYREALGDV
     VGDYNFICPA LEFTKKFSEW GNNAFFYYFE HRSSKLPWPE WMGVMHGYEI EFVFGLPLER
     RDNYTKAEEI LSRSIVKRWA NFAKYGNPNE TQNNSTSWPV FKSTEQKYLT LNTESTRIMT
     KLRAQQCRFW TSFFPKVLEM TGNIDEAEWE WKAGFHRWNN YMMDWKNQFN DYTSKKESCV
     GL
//
